Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.67 |
| ▸ | LMNA | P02545 | 7/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.67 |
| ▸ | APLNR | P35414 | 1/20 | 0.67 |
| ▸ | CCR6 | P51684 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | GRN | P28799 | 1/20 | 0.58 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | GRM5 | P41594 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | RPA1 | P27694 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28203159 | 0.90 | ALDH1A1 (0.67) | ALDH1A1LMNASMN1; SMN2CXCR5APLNR | |
| SCHEMBL26342422 | 0.89 | MEN1 (0.62) | ALDH1A1LMNASMN1; SMN2CXCR5APLNR | |
| SCHEMBL27172726 | 0.87 | ALDH1A1 (0.63) | ALDH1A1LMNASMN1; SMN2CXCR5APLNR | |
| SCHEMBL19002413 | 0.87 | LMNA (0.63) | ALDH1A1LMNASMN1; SMN2CXCR5APLNR | |
| SCHEMBL16112358 | 0.84 | LMNA (0.72) | ALDH1A1LMNASMN1; SMN2CXCR5APLNR | |
| SCHEMBL18997227 | 0.83 | LMNA (0.59) | ALDH1A1LMNASMN1; SMN2CXCR5APLNR | |
| SCHEMBL15074531 | 0.82 | ALDH1A1 (0.50) | ALDH1A1LMNASMN1; SMN2CXCR5APLNR | |
| SCHEMBL6365513 | 0.81 | KMT2A (0.59) | ALDH1A1LMNASMN1; SMN2CXCR5APLNR | |
| SCHEMBL26341512 | 0.81 | LMNA (1.00) | ALDH1A1LMNASMN1; SMN2CXCR5APLNR | |
| SCHEMBL26341994 | 0.80 | ALDH1A1 (0.56) | ALDH1A1LMNASMN1; SMN2CXCR5APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110922359-A | Pyrazole derivative compound, preparation method and application thereof | 东北农业大学 | 2020-03-27 | — | — | CN | disclosed |
| US-20120302581-A1 | Methods and Compositions for the Treatment of RAS Associated Disorders | THE TRUSTEES OF DARTMOUTH COLLEGE | 2012-11-29 | — | — | US | disclosed |
| US-20120302581-A1 | Methods and Compositions for the Treatment of RAS Associated Disorders | THE TRUSTEES OF DARTMOUTH COLLEGE | 2012-11-29 | — | — | US | disclosed |
| EP-1917262-B1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-12-14 | — | — | EP | disclosed |
| CN-101812019-A | Compound containing pyrazole ring geranyl formate, preparation method and applications thereof | UNIV CHINA AGRICULTURAL | 2010-08-25 | — | — | CN | disclosed |
| WO-2010015656-A2 | NEW ALKOXYPYRAZOLES | INSTITUT PASTEUR (FR) | 2010-02-11 | — | — | WO | disclosed |
| US-7491821-B2 | 2-(4-fluorophenyl)-4-propyl-oxazole-5-carboxylic acid {2-[4-(6-aminopyridin-2-yl)-piperazin-1-yl]-1-methyl-ethyl}amide; purinergic receptor antagonists, analgesics; urogenital, gastointestinal and respiratory system disorders | ROCHE PALO ALTO LLC (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1917262-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007020194-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037974-A1 | Inhibitors of P2X3 | ROCHE PALO ALTO LLC | 2007-02-15 | — | — | US | disclosed |
| CN-1731994-A | Prophylactic and therapeutic agent for neuropathy | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2006-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037974-A1 | Inhibitors of P2X3 | P2RX3, P2RX4, P2RX5 | ALDH1A1 2159/4885LMNA 3865/4885SMN1; SMN2 3624/4885 |
| US-20120302581-A1 | Methods and Compositions for the Treatment of RAS Associated Disorders | NRAS, HRAS, KRAS | ALDH1A1 3966/4885LMNA 3225/4885SMN1; SMN2 1031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.